( August 9, 2024, 22:31 GMT | Official Statement) -- MLex Summary: End-payor and direct purchaser plaintiffs bringing US antitrust claims against Takeda over its diabetes drug Actos should be granted class certification, a federal magistrate judge recommended. If approved, the end payor class would include any entity that, for consumption by their members, insureds, or beneficiaries, paid and/or provided reimbursement for some or all of the purchase price of Actos or generic pioglitazone between January 2011 and December 2015. The direct purchaser class would include anyone who purchased Actos or its AB-rated generic equivalent directly from Takeda or any generic manufacturer between January 2011 and January 2013.See document below. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.